Success Metrics

Clinical Success Rate

66.7%

Based on 2 completed trials

Completion Rate

67%(2/3)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Terminated

1(33%)

Phase Distribution

Ph phase_3

100%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 3Large-scale testing

3(100.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(2)

Terminated(1)

Detailed Status

Completed2

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

66.7%

Most Advanced

Phase 3

Trials by Phase

Phase 33 (100.0%)

Trials by Status

terminated133%

completed267%

Recent Activity

0 active trials

Showing 3 of 3

completedphase_3

Efficacy and Safety Study of Intravitreal Triamcinolone to Treat Diffuse Diabetic Macular Edema

NCT00309192

completedphase_3

Safety and Efficacy of Triamcinolone Acetonide Combined With Laser, Bevacizumab Combined With Laser Versus Laser Alone for the Treatment of Diffuse Non-tractional Diabetic Macular Edema

NCT01572350

terminatedphase_3

Combined Vitrectomy and Triamcinolone in Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)

NCT00642226

Clinical Trials (3)

Showing 3 of 3 trials

NCT00309192Phase 3

Efficacy and Safety Study of Intravitreal Triamcinolone to Treat Diffuse Diabetic Macular Edema

Completed

NCT01572350Phase 3

Safety and Efficacy of Triamcinolone Acetonide Combined With Laser, Bevacizumab Combined With Laser Versus Laser Alone for the Treatment of Diffuse Non-tractional Diabetic Macular Edema

Completed

NCT00642226Phase 3

Combined Vitrectomy and Triamcinolone in Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)

Terminated

All 3 trials loaded

Drug Details

Intervention Type: PROCEDURE
Total Trials: 3